Blurbs

Analysts Offer Insights on Healthcare Companies: Vyant Bio (VYNT), Minerva Neurosciences (NERV) and Cerevel Therapeutics Holdings (CERE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vyant Bio (VYNTResearch Report), Minerva Neurosciences (NERVResearch Report) and Cerevel Therapeutics Holdings (CEREResearch Report).

Vyant Bio (VYNT)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Vyant Bio, with a price target of $3.00. The company’s shares closed last Monday at $0.73, close to its 52-week low of $0.60.

According to TipRanks.com, White ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.3% and a 30.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Currently, the analyst consensus on Vyant Bio is a Moderate Buy with an average price target of $3.00.

See today’s best-performing stocks on TipRanks >>

Minerva Neurosciences (NERV)

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Minerva Neurosciences today and set a price target of $24.00. The company’s shares closed last Monday at $4.59, close to its 52-week low of $2.51.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 42.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Apellis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Minerva Neurosciences with a $17.00 average price target, representing a 416.7% upside. In a report issued on August 10, BTIG also maintained a Buy rating on the stock with a $6.00 price target.

Cerevel Therapeutics Holdings (CERE)

Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Cerevel Therapeutics Holdings today and set a price target of $32.00. The company’s shares closed last Monday at $32.60.

According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of -0.1% and a 47.1% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Bioxcel Therapeutics.

Currently, the analyst consensus on Cerevel Therapeutics Holdings is a Moderate Buy with an average price target of $42.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VYNT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos